Willow Biosciences Inc. WLLW Archives

FridayNov 13, 2020 12:26 pm

QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Q3 2020 Results, Operational Update

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, has released its financial and operating results for the three and nine months ended September 30, 2020. According to the update, Willow Biosciences reported significant advancement in its operations and strong liquidity. The update reads, “The third quarter represented another significant move forward for us, as we completed our first pilot campaign as part of our final development stage before we begin commercial production, which is anticipated to commence around the middle of 2021. From the pilot, and with our well-advanced downstream…

ThursdayOct 29, 2020 1:56 pm

QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Secures $11.5M in Upsized Public Offering

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, has closed its previously announced upsized public offering of 17,692,307 units of the company, each at a price of $0.65, including 2,307,692 units issued pursuant to the full exercise of the over-allotment option. The company secured aggregate gross proceeds of approximately $11.5 million in the offering. Williow Biosciences expects to use net proceeds for the commercialization of cannabigerol (“CBG”) and other portfolio cannabinoids of the company, general and administrative expenses, working capital and general corporate purposes. To view the full press release,…

ThursdayOct 08, 2020 10:37 am

QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) to Support Research on Therapeutic Potential of Non-Psychoactive Cannabinoids

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced its partnership with researchers at the University of Lethbridge and the University of Calgary. According to the update, the collaboration is designed to study the therapeutic potential of non-psychoactive cannabinoids in relation to intestinal inflammation, abdominal pain and depression. Alberta Innovates financially supports these studies that involve laboratory testing in preclinical models of disease. Willow will be providing four different, non-plant derived cannabinoids for use in the study, which is set to begin in the fourth quarter of 2020. “Willow…

MondaySep 14, 2020 11:08 am

QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) to Webcast Live at Life Sciences Investor Forum

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), based in Vancouver, Canada, focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced that its president and CEO, Trevor Peters, will present live at LifeSciencesInvestorForum.com at 2:30 p.m. ET on September 17, 2020. Interested parties may register for and access the presentation at http://ibn.fm/Fg5VX. Investors are invited to ask the company real-time questions at the live, interactive online event. An archived webcast will be available after the event for those unable to attend live on the day of the conference. To view the full press release, visit http://ibn.fm/JGXLR About Willow Biosciences Inc. Willow…

TuesdaySep 08, 2020 9:55 am

QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) to Receive Advisory Services, Funding for Rare Cannabinoid Development Platform

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), today announced that its subsidiary, Willow Analytics Inc., will receive advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") supporting a research and development project to advance production of its varin cannabinoids using its proprietary biosynthetic platform. "We welcome the advice and funding from NRC IRAP to support our rare cannabinoid development platform," said Dr. Mathias Schuetz, Willow's vice president of Research and Development, in the news release. "This support is an important catalyst for us to advance our strain development capabilities and will enable…

WednesdayJul 22, 2020 9:40 am

QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Moves to the Top of the OTC Market

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) this morning announced that it has been approved to commence trading on the OTCQX(R) Best Market (the "OTCQX") under the symbol "CANSF,” beginning today, July 22, 2020. Willow has upgraded to the OTCQX from the OTCQB(R) Venture Market (the "OTCQB"). "We are very excited to migrate to the top of the OTC market, the OTCQX(R) Best Market," Trevor Peters, president and CEO of Willow, stated in the news release. "This is a key milestone for us and allows for prospective U.S. investors to more easily invest in the Company. It is also a testament…

MondayJul 06, 2020 2:29 pm

QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) to Present at VirtualInvestorConferences.com

Willow Biosciences (TSX: WLLW) (OTCQB: CANSF), based in Vancouver, Canada, focused on manufacturing pharmaceutical grade quality cannabinoids via synthetic biology, today announced that its CEO and President Trevor Peters will present live at VirtualInvestorConferences.com at 12:00 p.m. Eastern Time on Thursday, July 9. Interested parties are encouraged to visit www.VirtualInvestorConferences.com to pre-register and run the online system check to expedite participation and receive event updates. An archived webcast will be made available after the event for those unable to join live on the day of the conference. To view the full press release, visit http://ibn.fm/n25lQ About Willow Biosciences Inc. Willow…

TuesdayJun 23, 2020 10:38 am

QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) Appoints New SVP to Lead Sales and Marketing of New Line of Cannabinoids

Willow Biosciences (TSX: WLLW) (OTCQB: CANSF) on Monday announced that Christopher Speed has joined the Company as Senior Vice President, Sales and Marketing, effective July 1, 2020. In this role, Speed will be responsible for leading the sales and marketing of Willow's new line of cannabinoids, along with the Company's strategic planning and customer initiatives. “We are very excited to have Chris join our team,” Trevor Peters, president and CEO of Willow, stated in the news release. “His expertise and experience in sales and marketing along with his strong background in the ingredients space with consumer packaged goods will be…

WednesdayJun 17, 2020 11:27 am

QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) Announces Further Acceleration of Path to Commercialization, Expands Portfolio

Willow Biosciences (TSX: WLLW) (OTCQB: CANSF), a Canadian biotechnology company creating high purity, plant-derived compounds for the global pharmaceutical, health and wellness and consumer packaged goods industries, today announced further acceleration of its path to commercialization following continued scale-up development success and the addition of multiple new cannabinoids for production. "Willow's scientific and operational success to date has solidified the use of yeast fermentation as a production platform," Willow's CEO Trevor Peters stated in the news release. "Our scientific discoveries over the past 14 months have contributed to the development of not one, but five different cannabinoids and our pilot…

FridayDec 13, 2019 2:41 pm

QualityStocksNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Holds Potential to Supply Biosynthetically Derived Cannabinoids

Willow Biosciences (CSE: WLLW) (OTCQB: CANSF), an emerging biotechnology company focused on the biosynthetic production of cannabinoids, is well positioned to disrupt the cannabis industry supply chain by utilizing its ability to provide biosynthetically derived cannabinoids. A recent article discussing the company reads, “Willow ultimately intends to biosynthetically produce a variety of cannabinoids using biosynthesis, but its first target molecule will be CBD. The company has a fully integrated leadership team based out of Canada and the United States to handle all stages of the upstream cannabinoid development cycle. Additionally, by having two labs in Canada, where cannabis is federally…

Site Search

Company Search

Tag: Willow Biosciences Inc. WLLW